Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 5Terminated 3Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 52Recurrence 6Neoplasms, Plasma Cell 5Neoplasms 3Immunoglobulin Light-chain Amyloidosis 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Lymphoma, Mantle-Cell 2Lymphoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphadenopathy 1Leukemia, Myeloid, Acute 1Leukemia 1HIV Infections 1

Interventions

Etoposide 5Cyclophosphamide 5Vincristine 4Methotrexate 4Doxorubicin 4Cytarabine 4pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Leucovorin 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3Calcium Dobesilate 3venetoclax 2prednylidene 2exifone 2deltacortene 2calaspargase pegol 2azathiopurine 2Whole-Body Irradiation 2Thioguanine 2Tacrolimus 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Bortezomib × Clear all
NCT02112916 2026-06-03

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
847 enrolled 19 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡